Echtzeit-Aktienkurs Portola Pharmaceuticals Inc.
Bid:
Ask:
Echtzeit-Chart der Portola Pharmaceuticals Inc. Aktie
Fundamentaldaten der Portola Pharmaceuticals Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2019 [USD] | 116,64 Mio. | -292,88 Mio. | -290,66 Mio. | -4,06 | - | - | - |
| 2018 [USD] | 40,13 Mio. | -350,54 Mio. | -350,22 Mio. | -5,31 | - | - | - |
| 2017 [USD] | 22,55 Mio. | -285,62 Mio. | -286,09 Mio. | -4,81 | - | - | - |
| 2016 [USD] | 35,50 Mio. | -268,11 Mio. | -269,04 Mio. | -4,76 | - | - | - |
| 2015 [USD] | 12,07 Mio. | -226,87 Mio. | -226,51 Mio. | -4,36 | - | - | - |
| 2014 [USD] | 9,63 Mio. | -137,13 Mio. | -137,13 Mio. | -3,19 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der Portola Pharmaceuticals Inc. Aktie
Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers includin